Jounce Therapeutics

Jounce Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. Founded in 2013 by prominent immunologists, the company leverages insights into the tumor microenvironment to discover and develop therapies designed to enable the immune system to attack tumors. Its pipeline includes candidates targeting pathways such as ICOS and CCR8, with a strategic emphasis on identifying predictive biomarkers to guide patient selection.

Company overview

Jounce Therapeutics was established in 2013 through the convergence of foundational research from its scientific founders, including University of Chicago professor Thomas F. Gajewski and Nobel laureate James P. Allison. Headquartered in the biotechnology hub of Cambridge, Massachusetts, the company has been led by Chief Executive Officer Richard Murray, who previously held leadership roles at Genentech. The firm's foundational science is deeply rooted in understanding the complex biology of the tumor microenvironment, particularly the distinctions between "T-cell-inflamed" and "non-T-cell-inflamed" tumors. This approach aims to move beyond one-size-fits-all immunotherapy and develop more precise treatments, a strategy that attracted early investment from entities like Third Rock Ventures and later led to a successful initial public offering on the NASDAQ in 2017.

Research and development

The research and development strategy is centered on translating discoveries in immuno-oncology into differentiated therapeutic candidates. A core platform involves the use of translational science tools to deeply profile patient samples, aiming to identify key mechanisms of immune resistance within tumors. This work has led to a pipeline targeting specific immune cell populations and signaling nodes. Key programs include JTX-8064, a monoclonal antibody designed to bind to the LILRB2 receptor on tumor-associated macrophages to repolarize them to an anti-tumor state. Another significant candidate is vopratelimab, a monoclonal antibody agonist targeting the ICOS receptor, intended to activate a specific subset of CD4 T cells. The company also advanced JTX-4014, a program targeting the PD-1 immune checkpoint, though its development was later discontinued to prioritize other assets.

Clinical trials

Jounce Therapeutics has progressed several candidates into human studies, often employing biomarker-driven designs. The vopratelimab program was evaluated in the phase 2 EMERGE trial, which combined the drug with the PD-1 inhibitor nivolumab in patients with non-small cell lung cancer. This study utilized a companion diagnostic to select patients based on a pre-defined ICOS biomarker signature. The company also initiated the phase 1 INNATE trial for JTX-8064 as a monotherapy and in combination with pembrolizumab across various advanced solid tumors. Additionally, a phase 1 trial was conducted for JTX-4014, the internal PD-1 antibody, though further development was halted. These clinical efforts are closely integrated with the company's translational research to generate data on pharmacodynamic effects and potential predictive biomarkers.

Collaborations and partnerships

To advance its programs and leverage external expertise, Jounce Therapeutics has engaged in several strategic collaborations. A significant partnership was formed with Celgene Corporation, which was later acquired by Bristol Myers Squibb. This multi-target alliance provided funding for research and development and included an option for Bristol Myers Squibb to license certain programs, including vopratelimab. The company also entered into a collaboration with Gilead Sciences focused on the development of JTX-8064. Furthermore, Jounce has engaged in research collaborations with academic institutions and diagnostic companies to support its biomarker strategies. These partnerships have been instrumental in providing non-dilutive capital and access to broader development capabilities within the pharmaceutical industry.

Corporate affairs

The corporate strategy has involved significant pipeline prioritization and strategic shifts in response to clinical data and the evolving immuno-oncology landscape. Following a review of its portfolio, the company discontinued development of JTX-4014 and deprioritized vopratelimab to concentrate resources on JTX-8064 and its CCR8 program. These decisions were communicated to shareholders and the market as part of a focused resource allocation plan. Leadership, under CEO Richard Murray, has navigated these changes while managing financial operations, including raising capital through public market offerings and partnership milestones. The company maintains its research facilities in Cambridge, Massachusetts, contributing to the local ecosystem of biotechnology innovation alongside neighbors like Moderna and Biogen.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Immunotherapy companies